Hepatitis B Virus Infection

Acute hepatitis B virus (HBV) infection is a short-term illness with an incubation period of 45 to 180 days, typically presenting with symptoms such as jaundice, fatigue, and elevated liver enzymes, and may progress to chronic infection if HBsAg persists beyond six months. Chronic HBV infection is a long-term condition that can lead to serious complications including cirrhosis and hepatocellular carcinoma, often remaining asymptomatic and undiagnosed for years. Most adults with acute HBV recover spontaneously and develop lifelong immunity, while only about 1% develop acute liver failure. Universal vaccination of newborns has reduced incidence, but many adults remain unvaccinated and at risk. Antiviral therapy is generally not required for acute HBV due to high spontaneous recovery rates, though it may be considered in cases of severe acute liver failure.

References:

[1]. Acute Hepatitis B. sciencedirect.

Hepatitis B Virus Infection (17):

Targets:	HBV (13) IFNAR (3) DNA/RNA Synthesis (3) Fluorescent Dye (1) Cytochrome P450 (1) Aminopeptidase (1) Biochemical Assay Reagents (1) HIV (1) JAK (1) Monoamine Oxidase (1) Nucleoside Antimetabolite/Analog (1) STAT (1) STING (1) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (1)

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure

HY-148560A

trans-ccc_R08	2413192-49-9	99.71%
trans-ccc_R08 (Compound 1-B) is a cccDNA inhibitor with anti-HBV activity, with an IC₅₀ of 0.14 μM for HBeAg and an IC₅₀ of 0.08 μM for HBsAg in in vitro assays. trans-ccc_R08 inhibits covalently closed circular DNA (cccDNA). trans-ccc_R08 is applicable to research related to hepatitis B virus infection.

HY-145638

Xalnesiran	2538784-48-2
Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection.

HY-145638A

Xalnesiran sodium	2538784-49-3
Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome. Xalnesiran sodium can be used for the research of chronic hepatitis B infection.

HY-P991112

Anti-Mouse CD8α Antibody (YTS169.4)		98.99%
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8⁺ T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection. Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-114247

FMAU	69256-17-3	99.04%
FMAU is a nucleoside analog and cell proliferation marker that can be phosphorylated by human thymidine kinase and subsequently incorporated into DNA. FMAU is applicable to research related to herpes simplex virus infection, various cancers, hepatitis B virus infection, and Epstein-Barr virus infection.

HY-128854

Dimethyl biphenyl-4,4'-dicarboxylate	792-74-5	99.85%
Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotective agent. Dimethyl biphenyl-4,4'-dicarboxylate stimulates the Jak/Stat signaling pathway and induces the expression of IFN-α-stimulated genes, particularly 6-16 and ISG12. Dimethyl biphenyl-4,4'-dicarboxylate inhibits the replication of pregenomic RNA and HBeAg. Polymer micelles loaded with Dimethyl biphenyl-4,4'-dicarboxylate can serve as carriers for the compound. Dimethyl biphenyl-4,4'-dicarboxylate can be used as an auxiliary improving agent for chronic hepatitis. Dimethyl biphenyl-4,4'-dicarboxylate is applicable to research related to chronic hepatitis B.\n

HY-P992458

SBT8230
SBT8230 is an ASGR1-targeted TLR8 agonist and an ASGR1-TLR8 immune TAC conjugate. SBT8230 achieves liver enrichment via conjugation with an anti-ASGR1 antibody, activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The corresponding isotype control is: Human lgG1 kappa,lsotype Control (HY-P99001).

HY-D3191

L&M-D-MR
L&M-D-MR is a highly specific fluorescent "AND" logic probe with response moieties for leucine aminopeptidase (LAP) and monoamine oxidase (MAO). The coexistence of both LAP and MAO is required for L&M-D-MR to trigger intramolecular cyclization, release fluorophores and activate fluorescence. In the presence of only a single enzyme, L&M-D-MR generates only an extremely weak signal. L&M-D-MR enables bioimaging in living cells and mouse models, and can effectively distinguish different subtypes of liver diseases via blood samples or test strips. L&M-D-MR is widely used in studies related to liver cirrhosis, hepatitis B and drug-induced liver injury.

HY-180524

CAB7-3	3014372-17-6
CAB7-3 is an orally active HBV capsid assembly modulator (CAM). CAB7-3 exhibits an exceptional antiviral efficacy reducing HBV DNA with an EC₅₀ = 70 nM, CC₅₀ = 32.3 μM in HepDES19 cells. CAB7-3 exhibits significant anti-HBV activity in HBV-integrated HepDES19 (EC₅₀ = 70 nM), HepAD38 (EC₅₀ = 1 nM) and HBV-infected HLCZ01 cells (EC₅₀ = 2 nM), respectively. CAB7-3 effectively reduces Hepatic HBV core protein levels and suppresses viral replication in vivo. CAB7-3 demonstrates a favorable drug-like and safety profile. CAB7-3 can be used for Hepatitis B Virus (HBV) research.

HY-16680

Helioxanthin 8-1	840529-13-7	98.58%
Helioxanthin 8-1(Helioxanthin analogue 8-1) is an anti-HBV agent. Helioxanthin 8-1 exhibits anti-hepatitis B virus activity in both in vitro human hepatitis B virus models and animal models. Helioxanthin 8-1 inhibits the synthesis of duck hepatitis B virus (DHBV) DNA, covalently closed circular DNA, RNA and proteins, thereby blocking DHBV replication. Helioxanthin 8-1 shows higher cytotoxicity in virus-induced cells than in non-induced cells. Helioxanthin 8-1 can be used in studies related to hepatitis B virus infection.

HY-108839

Peginterferon alfa-2a	198153-51-4
Peginterferon alfa-2a is a PEG-modified interferon (IFN) alpha-2a. Peginterferon alfa-2a can be used for research of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection.

HY-183260

HBV-IN-57	3049354-73-3
HBV-IN-57 is an orally active HBV inhibitor with pan-genotypic efficacy against HBV genotypes B/C. HBV-IN-57 inhibits HBV DNA replication and HBV capsid assembly. HBV-IN-57 can be used for the research of chronic hepatitis B.

HY-N17557

Schizanrin D	343326-65-8
Schizanrin D (Schizarin D) is a C₁₈ Dibenzocyclooctadiene lignin. Schizanrin D can be derived from dried stems of Kadsura matsudai. Schizanrin D inhibits HBeAg production. Schizanrin D is inactive in vitro against HIV replication.

HY-183576

HBsAg-IN-1
HBsAg-IN-1 is an orally active, highly liver-selective inhibitor of HBsAg production, with an EC₅₀ of 0.63 nM. HBsAg-IN-1 shows no neurite growth inhibitory activity. HBsAg-IN-1 can be used in studies related to hepatitis B virus (HBV) infection.

HY-181348

HBV-IN-56	2564693-71-4
HBV-IN-56 is an orally active HBsAg production inhibitor. HBV-IN-56 inhibits HBsAg production both in vitro and in vivo. HBV-IN-56 can be used for the research of chronic hepatitis B virus infection.

HY-177378

HBV-IN-53	2243162-67-4
HBV-IN-53 (Compound 1) is an HBV inhibitor. HBV-IN-53 reduces the level of HBV DNA in serum. The inhibitory activity of HBV-IN-53 in combination with Tenofovir disoproxil fumarate (HY-13782) exhibits an additive effect on HBV inhibition.

HY-N8107

Matairesinol monoglucoside	34446-06-5	99.42%
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection.

Name
Email *

	Sorry, but the email address you supplied was invalid.